Program
BI 764524
A development code.
In Boehringer Ingelheim's pipeline, Sema3A antibody
. Its studies are mostly in Diabetic Retinopathy, led by Boehringer Ingelheim.
Furthest: phase 2, since Jun 8, 20202 company-led studies, 1 open or runningNext primary completion: Mar 5, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 21 open or running | phase 2since Jun 8, 2020 | Jun 8, 2020 | Mar 5, 2027phase 2 · NCT06321302 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 764524
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 8, 2020First study: phase 2 study in Diabetic RetinopathyFirst studyNCT04424290 · 45 enrolled · United States, United Kingdom
- Mar 14, 2024Phase 2 study in Diabetic RetinopathyNCT06321302 · 175 planned · United States, Germany, Hungary and more
Ahead
- Mar 5, 2027Primary completion: phase 2 study in Diabetic RetinopathyNCT06321302
TargetBeta
“Sema3A antibody”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06321302Diabetic Retinopathy · United States, Germany, Hungary and more | 2 | Recruiting | Mar 5, 2027 | 175 |
| NCT04424290Diabetic Retinopathy · United States, United Kingdom | 2 | Completed | Apr 28, 2023 | 45 |
How it is read
Names in the registry
- “BI 764524”, 2 entries
Codes read as this program: BI764524.
Conditions, from the studies’ own filings
- Diabetic Retinopathy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.